Trade Report: Today, Bristol-Myers Squibb Co. (BMY) Lowered by Vetr Inc. to Buy

Today, Bristol-Myers Squibb Co. (BMY) Lowered by Vetr Inc. to Buy

Bristol-Myers Squibb Co. (NYSE:BMY) was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Monday. They presently have a $58.77 price target on the biopharmaceutical company’s stock. Vetr‘s price target indicates a potential upside of 3.14% from the company’s current price.

A number of other analysts also recently weighed in on the company. Credit Suisse Group AG downgraded Bristol-Myers Squibb from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $86.00 to $63.00 in a research note on Sunday, August 7th. Leerink Swann restated an “outperform” rating and issued a $69.00 price target on shares of Bristol-Myers Squibb in a research note on Sunday, October 9th. Morgan Stanley restated a “hold” rating on shares of Bristol-Myers Squibb in a research note on Thursday, August 25th. Jefferies Group restated a “hold” rating and issued a $57.00 price target (down from $69.00) on shares of Bristol-Myers Squibb in a research note on Monday, September 12th. Finally, Goldman Sachs Group Inc. restated a “buy” rating and issued a $75.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, September 27th. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $67.51.

Shares of Bristol-Myers Squibb (NYSE:BMY) traded up 0.41% during mid-day trading on Monday, hitting $56.98. The company’s stock had a trading volume of 6,228,571 shares. The company has a market cap of $95.23 billion, a PE ratio of 28.50 and a beta of 0.90. The stock has a 50-day moving average of $52.69 and a 200-day moving average of $63.10. Bristol-Myers Squibb has a 12-month low of $49.03 and a 12-month high of $77.12.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 27th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.12. Bristol-Myers Squibb had a return on equity of 28.98% and a net margin of 18.54%. The business had revenue of $4.83 billion for the quarter, compared to analyst estimates of $4.76 billion. During the same quarter in the previous year, the company posted $0.39 earnings per share. The company’s revenue for the quarter was up 21.0% compared to the same quarter last year. On average, equities research analysts forecast that Bristol-Myers Squibb will post $2.85 EPS for the current year.

In other news, Director Lamberto Andreotti sold 21,600 shares of the company’s stock in a transaction dated Thursday, September 8th. The stock was sold at an average price of $56.87, for a total value of $1,228,392.00. Following the completion of the sale, the director now owns 334,499 shares of the company’s stock, valued at $19,022,958.13. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.24% of the stock is owned by insiders.

Large investors have recently modified their holdings of the company. Cupps Capital Management LLC increased its position in shares of Bristol-Myers Squibb by 12.0% in the first quarter. Cupps Capital Management LLC now owns 5,200 shares of the biopharmaceutical company’s stock worth $332,000 after buying an additional 559 shares in the last quarter. Gardner Lewis Asset Management L P increased its position in shares of Bristol-Myers Squibb by 65.4% in the first quarter. Gardner Lewis Asset Management L P now owns 83,028 shares of the biopharmaceutical company’s stock worth $5,304,000 after buying an additional 32,833 shares in the last quarter. Meeder Asset Management Inc. increased its position in shares of Bristol-Myers Squibb by 373.4% in the first quarter. Meeder Asset Management Inc. now owns 45,771 shares of the biopharmaceutical company’s stock worth $2,924,000 after buying an additional 36,102 shares in the last quarter. Scotia Capital Inc. increased its position in shares of Bristol-Myers Squibb by 18.9% in the first quarter. Scotia Capital Inc. now owns 59,133 shares of the biopharmaceutical company’s stock worth $3,780,000 after buying an additional 9,394 shares in the last quarter. Finally, Edmond DE Rothschild Holding S.A. increased its position in shares of Bristol-Myers Squibb by 7,804.2% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 202,664 shares of the biopharmaceutical company’s stock worth $12,946,000 after buying an additional 200,100 shares in the last quarter. 71.28% of the stock is owned by institutional investors.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Related posts

Leave a Comment